Analysis of therapeutic decision-making process and prognosis in patients referred to the Valvular Heart Team for management of mitral regurgitation

M.L. Marie Luciani
{"title":"Analysis of therapeutic decision-making process and prognosis in patients referred to the Valvular Heart Team for management of mitral regurgitation","authors":"M.L. Marie Luciani","doi":"10.1016/j.acvdsp.2023.04.003","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p><span>Due to the aging of the population and the diversification of treatment options, finding the right treatment for the right patient becomes a challenge, especially </span>in patients<span> with mitral regurgitation (MR), which is a heterogenous and complex disease, with numerous etiologies. Aims of this study are to describe the profile of patients referred to the Valvular Heart Team (VHT) for management of mitral regurgitation, to highlight the selection process and the main factors guiding allocation for different treatment options, to assess clinical outcomes after treatment.</span></p></div><div><h3>Method</h3><p>All patients with mitral regurgitation referred to the VHT between January 1st, 2014, and April 30th, 2021, in University Hospital of Tours, were included.</p></div><div><h3>Results</h3><p>MR patients referred to our VHT were, mostly, old (mean: 74.2 years), symptomatic (96%), at high or intermediate risk according to “European Society of Cardiology” criteria (44%). Most of them had comorbidities, 34% had LVEF<!--> <!-->&lt;<!--> <span>50% and 70% a severe primary MR. In 81% of cases, invasive management was decided (surgery [44%], percutaneous edge- to-edge mitral repair [TEER] [35%], transcatheter mitral valve replacement [1.6%]) and in 19% of cases, medical treatment was decided. Distribution of treatments changed significantly (</span><em>P</em> <!-->&lt;<!--> <!-->0.01) over time, with a progressive increase in TEER. History of cardiac surgery (<em>P</em> <!-->=<!--> <!-->0.015), EuroScore II<!--> <!-->&gt;<!--> <!-->4% (<em>P</em> <!-->=<!--> <span>0.012), STS score &gt; 8% (</span><em>P</em> <!-->=<!--> <span>0.037), frailty<span> according to the Katz index (</span></span><em>P</em> <!-->=<!--> <!-->0.029), LVEF &lt; 50% (<em>P</em> <!-->&lt;<!--> <!-->0.001), TAPSE<!--> <!-->&lt;<!--> <!-->15 mm (<em>P</em> <!-->&lt;<!--> <!-->0,01) secondary MR (<em>P</em> <!-->&lt;<!--> <!-->0.001) and leaflets calcifications (<em>P</em> <!-->=<!--> <!-->0.027) were the main factors significantly associated with the choice of a conservative treatment. In 86% of cases, VHT decisions could be implemented.</p></div><div><h3>Conclusion</h3><p>VHT is a centerpiece in the current management of patients with MR, it opts and more and more, for percutaneous treatments. The organization and the smooth running of VHT meetings will be a real issue in the future, with the increase in patients referred and we will have to find solutions (<span>Fig. 1</span>).</p></div>","PeriodicalId":8140,"journal":{"name":"Archives of Cardiovascular Diseases Supplements","volume":"15 3","pages":"Pages 243-244"},"PeriodicalIF":18.0000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Cardiovascular Diseases Supplements","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1878648023001428","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

Due to the aging of the population and the diversification of treatment options, finding the right treatment for the right patient becomes a challenge, especially in patients with mitral regurgitation (MR), which is a heterogenous and complex disease, with numerous etiologies. Aims of this study are to describe the profile of patients referred to the Valvular Heart Team (VHT) for management of mitral regurgitation, to highlight the selection process and the main factors guiding allocation for different treatment options, to assess clinical outcomes after treatment.

Method

All patients with mitral regurgitation referred to the VHT between January 1st, 2014, and April 30th, 2021, in University Hospital of Tours, were included.

Results

MR patients referred to our VHT were, mostly, old (mean: 74.2 years), symptomatic (96%), at high or intermediate risk according to “European Society of Cardiology” criteria (44%). Most of them had comorbidities, 34% had LVEF < 50% and 70% a severe primary MR. In 81% of cases, invasive management was decided (surgery [44%], percutaneous edge- to-edge mitral repair [TEER] [35%], transcatheter mitral valve replacement [1.6%]) and in 19% of cases, medical treatment was decided. Distribution of treatments changed significantly (P < 0.01) over time, with a progressive increase in TEER. History of cardiac surgery (P = 0.015), EuroScore II > 4% (P = 0.012), STS score > 8% (P = 0.037), frailty according to the Katz index (P = 0.029), LVEF < 50% (P < 0.001), TAPSE < 15 mm (P < 0,01) secondary MR (P < 0.001) and leaflets calcifications (P = 0.027) were the main factors significantly associated with the choice of a conservative treatment. In 86% of cases, VHT decisions could be implemented.

Conclusion

VHT is a centerpiece in the current management of patients with MR, it opts and more and more, for percutaneous treatments. The organization and the smooth running of VHT meetings will be a real issue in the future, with the increase in patients referred and we will have to find solutions (Fig. 1).

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
瓣膜心脏团队治疗二尖瓣返流患者的治疗决策过程和预后分析
由于人口老龄化和治疗方案的多样化,为合适的患者找到合适的治疗方法成为一项挑战,特别是对于二尖瓣反流(MR)患者,这是一种异质性和复杂的疾病,病因众多。本研究的目的是描述转介到瓣膜性心脏小组(VHT)治疗二尖瓣返流的患者概况,强调选择过程和指导分配不同治疗方案的主要因素,评估治疗后的临床结果。方法选取2014年1月1日至2021年4月30日在图尔大学医院行VHT就诊的所有二尖瓣返流患者。结果采用VHT治疗的smr患者大多为老年人(平均74.2岁),有症状(96%),根据欧洲心脏病学会(European Society of Cardiology)的标准(44%)具有高或中度风险。大多数患者有合并症,34%有LVEF <在81%的病例中,有创治疗被决定(手术[44%],经皮二尖瓣边缘到边缘修复[TEER][35%],经导管二尖瓣置换术[1.6%]),19%的病例被决定药物治疗。处理的分布发生了显著变化(P <0.01),随着时间的推移,TEER逐渐增加。心脏手术史(P = 0.015), EuroScore II >4% (P = 0.012), STS评分>8% (P = 0.037),根据Katz指数(P = 0.029), LVEF <50% (P <0.001), TAPSE <15mm (P <0.01)继发MR (P <0.001)和小叶钙化(P = 0.027)是选择保守治疗的主要因素。在86%的病例中,VHT判决可以得到执行。结论vht是目前MR患者治疗的核心,越来越多地选择经皮治疗。随着转诊患者的增加,未来VHT会议的组织和顺利进行将是一个真正的问题,我们必须找到解决方案(图1)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Archives of Cardiovascular Diseases Supplements
Archives of Cardiovascular Diseases Supplements CARDIAC & CARDIOVASCULAR SYSTEMS-
自引率
0.00%
发文量
508
期刊介绍: Archives of Cardiovascular Diseases Supplements is the official journal of the French Society of Cardiology. The journal publishes original peer-reviewed clinical and research articles, epidemiological studies, new methodological clinical approaches, review articles, editorials, and Images in cardiovascular medicine. The topics covered include coronary artery and valve diseases, interventional and pediatric cardiology, cardiovascular surgery, cardiomyopathy and heart failure, arrhythmias and stimulation, cardiovascular imaging, vascular medicine and hypertension, epidemiology and risk factors, and large multicenter studies. Additionally, Archives of Cardiovascular Diseases also publishes abstracts of papers presented at the annual sessions of the Journées Européennes de la Société Française de Cardiologie and the guidelines edited by the French Society of Cardiology.
期刊最新文献
Editorial Contents How to Report postoperative pediatric cardiac surgery? Review and analysis of the literature Surgical or transcatheter pulmonary valve replacement, how to choose ? No coronary artery in the aorta: Severe congenital malformation under-diagnosed
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1